Page last updated: 2024-10-21

pk 11195 and Ornithine Carbamoyltransferase Deficiency Disease

pk 11195 has been researched along with Ornithine Carbamoyltransferase Deficiency Disease in 1 studies

PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine

Ornithine Carbamoyltransferase Deficiency Disease: An inherited urea cycle disorder associated with deficiency of the enzyme ORNITHINE CARBAMOYLTRANSFERASE, transmitted as an X-linked trait and featuring elevations of amino acids and ammonia in the serum. Clinical features, which are more prominent in males, include seizures, behavioral alterations, episodic vomiting, lethargy, and coma. (Menkes, Textbook of Child Neurology, 5th ed, pp49-50)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rao, VL1
Qureshi, IA1
Butterworth, RF1

Other Studies

1 other study available for pk 11195 and Ornithine Carbamoyltransferase Deficiency Disease

ArticleYear
Increased densities of binding sites for the peripheral-type benzodiazepine receptor ligand [3H]PK 11195 in congenital ornithine transcarbamylase-deficient sparse fur mouse.
    Pediatric research, 1993, Volume: 34, Issue:6

    Topics: Amino Acid Metabolism, Inborn Errors; Ammonia; Animals; Binding Sites; Brain; Disease Models, Animal

1993